摘要:
The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
摘要:
The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
摘要:
The present invention relates to imidazo pyridine derivatives of the formula (I), in which the phenyl moiety is substituted with lower alkyl in 2- and 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
摘要:
The present invention relates to substituted imidazo [1,2-a]pyridines of formula I where R is —CH2COOH or —COOH, which inhibits exogenously or endogenously stimulated gastric acid secretion and can be used in the prevention and treatment of gastric acid related diseases and gastrointestinal inflammatory diseases.
摘要:
The present invention relates to substituted imidazo [1,2-a]pyridines of formula I where R is —CH2COOH or —COOH, which inhibits exogenously or endogenously stimulated gastric acid secretion and can be used in the prevention and treatment of gastric acid related diseases and gastrointestinal inflammatory diseases.
摘要:
Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
摘要:
The present invention relates to new salts of the single enantiomers of omeprazole, i.e. salts of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((S)-omeprazole) and (R)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((R)-omeprazole) respectively. More specifically, the present invention relates to 1-cyclohexylethyl ammonium salts of the compounds, formed by a reaction of (S)-omeprazole and (R)-omeprazole respectively and 1-cyclohexylethyl amine. The present invention also relates to a process for preparing the compounds of the invention, a pharmaceutical preparation and a method for treatment of gastric related disorders by administering the compounds of the invention.
摘要:
The present invention relates to new salts of omeprazole and esomeprazole respectively, i.e. salts of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole and the (S)-enantiomer thereof. More specifically, the present invention relates to adamantan ammonium salt of the compounds, formed by a reaction of omeprazole and esomeprazole respectively and adamantan amine. The present invention also relates to a process for preparing the compounds of the invention, a pharmaceutical preparation and a method for treatment of gastric related disorders by administering the compounds of the invention.
摘要:
The present invention relates to new salts of omeprazole and esomeprazole respectively, i.e. salts of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzirnidazole and the (S)-enantiomer thereof. More specifically, the present invention relates to alkylammonium salts of the compounds, formed by a reaction of omeprazole and esomeprazole respectively and an alkylamine with formula NR1R2R3, wherein R1 is a linear, branched, or cyclic C1-C12-alkyl group, and R2 and R3 are hydrogen. The present invention also relates to a process for preparing crystalline salts, a pharmaceutical preparation, and a method for treatment of gastric related disorders by administering the compound of the invention.
摘要翻译:本发明分别涉及奥美拉唑和艾美拉唑的新盐,即5-甲氧基-2 - [[(4-甲氧基-3,5-二甲基-2-吡啶基) - 甲基]亚磺酰基] -1H-苯并咪唑的盐和 (S) - 对映体。 更具体地,本发明涉及通过奥美拉唑和埃索美拉唑的反应形成的化合物的烷基铵盐和具有式NR 1 R 2 R 2的烷基胺, 其中R 1是直链,支链或环状的C 1 -C 12 - 烷基,R 1, SUB 2和R 3是氢。 本发明还涉及通过施用本发明的化合物制备结晶盐的方法,药物制剂和治疗胃相关疾病的方法。
摘要:
The present invention relates to heterocyclic compounds of the formula (I), in which the phenyl moiety is substituted with lower alkyl in 2- and 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.